Calculation of Phase 2 dose-finding study sample size for reliable Phase 3 dose selection

被引:0
作者
Liu, Fang [1 ,2 ]
Zhao, Qing [1 ]
Rodgers, Anthony J. [1 ]
Mehrotra, Devan V. [1 ]
机构
[1] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ USA
[2] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ 07065 USA
关键词
dose-finding study; MCP-Mod; Phase 3 dose selection; sample size determination; COMBINING MULTIPLE COMPARISONS; MODEL SELECTION; OPTIMAL DESIGNS;
D O I
10.1002/pst.2330
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sample sizes of Phase 2 dose-finding studies, usually determined based on a power requirement to detect a significant dose-response relationship, will generally not provide adequate precision for Phase 3 target dose selection. We propose to calculate the sample size of a dose-finding study based on the probability of successfully identifying the target dose within an acceptable range (e.g., 80%-120% of the target) using the multiple comparison and modeling procedure (MCP-Mod). With the proposed approach, different design options for the Phase 2 dose-finding study can also be compared. Due to inherent uncertainty around an assumed true dose-response relationship, sensitivity analyses to assess the robustness of the sample size calculations to deviations from modeling assumptions are recommended. Planning for a hypothetical Phase 2 dose-finding study is used to illustrate the main points. Codes for the proposed approach is available at .
引用
收藏
页码:1076 / 1088
页数:13
相关论文
共 17 条
[11]   Design and analysis of dose-finding studies combining multiple comparisons and modeling procedures [J].
Pinheiro, Jose ;
Bornkamp, Bjoern ;
Bretz, Frank .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2006, 16 (05) :639-656
[12]   Model-based dose finding under model uncertainty using general parametric models [J].
Pinheiro, Jose ;
Bornkamp, Bjoern ;
Glimm, Ekkehard ;
Bretz, Frank .
STATISTICS IN MEDICINE, 2014, 33 (10) :1646-1661
[13]   Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012 [J].
Sacks, Leonard V. ;
Shamsuddin, Hala H. ;
Yasinskaya, Yuliya I. ;
Bouri, Khaled ;
Lanthier, Michael L. ;
Sherman, Rachel E. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (04) :378-384
[14]   Model selection versus model averaging in dose finding studies [J].
Schorning, Kirsten ;
Bornkamp, Bjorn ;
Bretz, Frank ;
Dette, Holger .
STATISTICS IN MEDICINE, 2016, 35 (22) :4021-4040
[15]   Analysis of Clinical Dose-Response in Small-Molecule Drug Development: 2009-2014 [J].
Thomas, Neal ;
Roy, Dooti .
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2017, 9 (02) :137-146
[16]   Meta-Analysis of Clinical Dose-Response in a Large Drug Development Portfolio [J].
Thomas, Neal ;
Sweeney, Kevin ;
Somayaji, Veena .
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2014, 6 (04) :302-317
[17]  
USA Food and Drug Administration (FDA), 2016, STAT REV EV QUAL STA